Science Translational Medicine
19 June 2019 Vol 11, Issue 497
Vaccines and global health: In search of a sustainable model for vaccine development and delivery
By Rino Rappuoli, Steven Black, David E. Bloom
Science Translational Medicine19 Jun 2019 Restricted Access
Most vaccines for diseases in low- and middle-income countries fail to be developed because of weak or absent market incentives. Conquering diseases such as tuberculosis, HIV, malaria, and Ebola, as well as illnesses caused by multidrug-resistant pathogens, requires considerable investment and a new sustainable model of vaccine development involving close collaborations between public and private sectors.
…For vaccination programs to succeed, confidence in vaccines needs to be nurtured and the benefits of vaccination need to be effectively communicated. Successful examples, such as the New Zealand meningococcus B vaccine and U.K. meningococcus C vaccine, were supported by separate budgets for vaccine campaigns to communicate the importance of vaccination for public health. Dedicated investment for such vaccine campaigns is rare, but maintaining the confidence of the populace during vaccination efforts is key. Communication must be the exclusive domain of the public sector because the industry’s conflict of interest would render it untrustworthy for this purpose…
…The success of early-stage development efforts for new vaccines has resulted in an unexpected potential crisis on the back end of the process, resulting in a lack of capacity and resources to push vaccine candidates through late-stage development to market introduction. If we can tackle this crisis, then we can harness the promise of prospective vaccines to improve global health for all.